Management of complex treatment-resistant psychotic disorders / edited by Dr. Michael A. Cummings, Dr. Stephen M. Stahl.

Format:

Book

Contributor:

Cummings, Michael A. (Michael Allen), 1951- editor.

Stahl, Stephen M., 1951- editor.

Series:

Cambridge medicine (Series)

Cambridge medicine

Language:

English

Subjects (All):

Psychoses.

Physical Description:

1 online resource (xxii, 522 pages) : digital, PDF file(s).

Edition:

First edition.

Place of Publication:

Cambridge : Cambridge University Press, 2021.

Summary:

This full-color, practical handbook provides a concise, evidence-based psychopharmacological approach to the management of complex treatment-resistant psychotic disorders. Part I focuses uniquely on topics and strategies relevant to treating this challenging patient population. These approaches go beyond standard guidelines while adhering to research and clinically derived data. Part II provides a concise array of information regarding those classes of medications most commonly used when treating complex treatment-resistant psychotic disorders. Each medication guide contains sections including mechanisms of action, typical treatment response, monitoring, dosing and kinetics, medications to avoid in combination/warnings, and take-home pearls. Part III offers tips in brief appendix chapters for managing common issues ranging from loading lithium and valproic acid to the treatment of acute psychomotor agitation. An essential resource for psychiatrists, forensic clinicians, psychiatric trainees, and all mental health professionals involved with, or interested in, the treatment of challenging psychotic disorders.

Contents:

Cover

Half-title page

Title page

Copyright page

Contents

Contributors

Acknowledgements

List of Abbreviations

List of Icons

Introduction

Part I Treatment Strategies

1.01 Approaches to Positive Psychotic Symptoms

1.02 Use of Plasma Levels in Antipsychotic and Mood Stabilizer Treatment

1.03 Advantages of Long-Acting Injectable Antipsychotics

1.04 Approach to Treatment-Resistant Schizophrenia Spectrum Patients

1.05 Approach to Depressed or Suicidal Schizophrenia Spectrum Patients

1.06 Approach to Persistent Aggression and Violence in Schizophrenia Spectrum Psychotic Disorders

1.07 Approach to Bipolar Diathesis in Schizophrenia Spectrum Patients

1.08 Approach to Anxiety in Schizophrenia Spectrum Patients

1.09 Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum Disorders

1.10 Approach to Psychosis in Children and Adolescents

1.11 Electroconvulsive Therapy and Other Non-Pharmacological Treatments

1.12 Approach to Substance Use Disorders in Schizophrenia Spectrum Disorders

1.13 Approaches to Behavioral Disturbances in Dementia and Traumatic Brain Injury Patients

Part II Medication Reference Tables

First-Generation (Typical) Antipsychotics

2.01 Chlorpromazine

2.02 Fluphenazine

2.03 Haloperidol

2.04 Loxapine

2.05 Perphenazine

2.06 Thiothixene

2.07 Trifluoperazine

Second-Generation (Atypical) Antipsychotics

2.08 Asenapine

2.09 Clozapine

2.10 Iloperidone

2.11 Lumateperone

2.12 Lurasidone

2.13 Olanzapine

2.14 Paliperidone

2.15 Quetiapine

2.16 Risperidone

2.17 Ziprasidone

Dopamine Partial Agonist Antipsychotics

2.18 Aripiprazole

2.19 Brexpiprazole

2.20 Cariprazine

Medications for Motor/Neurologic Adverse Effects

2.21 Amantadine

2.22 Benztropine

2.23 Diphenhydramine

2.24 Trihexyphenidyl.

Mood Stabilizers

2.25 Carbamazepine

2.26 Lamotrigine

2.27 Lithium

2.28 Valproic Acid

Selective Serotonin Reuptake Inhibitor Antidepressants

2.29 Citalopram

2.30 Escitalopram

2.31 Fluoxetine

2.32 Fluvoxamine

2.33 Paroxetine

2.34 Sertraline

SSRI/5HT1A Partial Agonist Antidepressants

2.35 Vilazodone

2.36 Vortioxetine

Serotonin/Norepinephrine Reuptake Inhibitor Antidepressants

2.37 Desvenlafaxine

2.38 Duloxetine

2.39 Levomilnacipran

2.40 Venlafaxine

Mixed Mechanism Antidepressants

2.41 Bupropion

2.42 Mirtazapine

2.43 Trazodone

Tricyclic Antidepressants

2.44 Amitriptyline

2.45 Clomipramine

2.46 Desipramine

2.47 Doxepin

2.48 Imipramine

2.49 Nortriptyline

Monoamine Oxidase Inhibitor Antidepressants

2.50 Isocarboxazid

2.51 Moclobemide

2.52 Phenelzine

2.53 Transdermal Selegiline

2.54 Tranylcypromine

Anxiolytics

2.55 Alprazolam

2.56 Buspirone

2.57 Clonazepam

2.58 Diazepam

2.59 Hydroxyzine

2.60 Lorazepam

Sedatives

2.61 Diphenhydramine

2.62 Eszopiclone

2.63 Hydroxyzine

2.64 Lorazepam

2.65 Oxazepam

2.66 Temazepam

2.67 Zaleplon

2.68 Zolpidem

Circadian Regulators

2.69 Melatonin

2.70 Ramelteon

2.71 Tasimelteon

Stimulants

2.72 Atomoxetine

2.73 Dextroamphetamine

2.74 Lisdexamfetamine

2.75 Methylphenidate

2.76 Mixed Amphetamine Salts

Histaminic Stimulants

2.77 Armodafinil

2.78 Modafinil

Cognitive Agents

2.79 Dextromethorphan/Quinidine

2.80 Donepezil

2.81 Galantamine

2.82 Memantine

2.83 Rivastigmine

α2-Adrenergic Agonists

2.84 Clonidine

2.85 Guanfacine

Appendices

3.01 Optimal Antipsychotic Plasma Concentration Ranges

3.02 Optimal Mood Stabilizer Plasma Concentration Ranges

3.03 Formulas for Correcting QT Interval.

3.04 Common Cytochrome P450 Inducers and Inhibitors

3.05 Management of Constipation

3.06 Child-Pugh Hepatic Function Scoring

3.07 Loading of Lithium and Valproic Acid

3.08 Treatment of Prolactin Elevation

3.09 A Select List of Foods High in Tyramine

3.10 Medications That Present Risk for Serotonin Syndrome When Combined with Monoamine Oxidase Inhibitor

3.11 Selected Treatment of Psychomotor Agitation Algorithm

Index.

Notes:

Title from publisher's bibliographic system (viewed on 20 Oct 2021).

Includes bibliographical references.

ISBN:

9781108967044

1108967043

9781108962124

1108962122

9781108963923

1108963927